|
1) Ware LB, Matthay MA. The acute respiratory distress syndrome. N Engl J Med. 2000; 342: 1334-49
|
|
|
|
2) Tasaka S, Hasegawa N, Ishizaka A. Pharmacology of acute lung injury. Pulm Pharmacol Ther. 2002; 15: 83-95
|
|
|
|
|
|
3) McCall CE, Yoza BK. Gene silencing in severe systemic inflammation. Am J Respir Crit Care Med. 2007; 175: 763-7
|
|
|
|
|
|
4) Goodwin GH, Sanders C, Johns EW. A new group of chromatin-associated proteins with a high content of acidic and basic amino acids. Eur J Biochem. 1973; 38: 14-9
|
|
|
|
|
|
5) Scaffidi P, Misteli T, Bianchi ME. Release of chromatin protein HMGB1 by necrotic cells triggers inflammation. Nature. 2002; 418: 191-5
|
|
|
|
|
|
6) Andersson U, Wang H, Palmblad K, et al. High mobility group 1 protein (HMG-1) stimulates proinflammatory cytokine synthesis in human monocytes. J Exp Med. 2000; 192: 565-70
|
|
|
|
|
|
7) Harris HE, Andersson U. The nuclear protein HMGB1 as a proinflammatory mediator. Eur J Immunol. 2004; 34: 1503-12
|
|
|
|
|
|
8) Li J, Kokkola R, Tabibzadeh S, et al. Structural basis for the proinflammatory cytokine activity of high mobility group box 1. Mol Med. 2003; 9: 37-45
|
|
|
|
|
|
9) Hori O, Brett J, Slattery T, et al. The receptor for advanced glycation endproducts (RAGE) is a cellular binding site for amphoterin: mediation of neurite outgrowth and co-expression of RAGE and amphoterin in the developing nervous system. J Biol Chem. 1995; 270: 25752-61
|
|
|
|
|
|
10) Park JS, Svetkauskaite D, He Q, et al. Involvement of toll-like receptors 2 and 4 in cellular activation by high mobility group box 1 protein. J Biol Chem. 2004; 279: 7370-7
|
|
|
|
|
|
11) Lander HM, Tauras JM, Ogiste JS, et al. Activation of the receptor for advanced glycation end products triggers a p21(ras)-dependent mitogen-activated protein kinase pathway regulated by oxidant stress. J Biol Chem. 1997; 272: 17810-4
|
|
|
|
|
|
12) Ishihara K, Tsutsumi K, Kawane S, et al. The receptor for advanced glycation end-products (RAGE) directly binds to ERK by a D-domain-like docking site. FEBS Lett. 2003; 550: 107-13
|
|
|
|
|
|
13) Hudson BI, Kalea AZ, Del Mar Arriero M, et al. Interaction of the RAGE cytoplasmic domain with diaphanous-1 is required for ligand-stimulated cellular migration through activation of Rac1 and Cdc42. J Biol Chem. 2008; 283: 34457-68
|
|
|
|
|
|
14) Park JS, Arcaroli J, Yum HK, et al. Activation of gene expression in human neutrophils by high mobility group box 1 protein. Am J Physiol Cell Physiol. 2003; 284: C870-9
|
|
|
|
|
|
15) Park JS, Gamboni-Robertson F, He Q, et al. High mobility group box 1 protein interacts with multiple Toll-like receptors. Am J Physiol Cell Physiol. 2006; 290: C917-24
|
|
|
|
|
|
16) Wang H, Bloom O, Zhang M, et al. HMG-1 as a late mediator of endotoxin lethality in mice. Science. 1999; 285: 248-51
|
|
|
|
|
|
17) Suda K, Kitagawa Y, Ozawa S, et al. Anti-high-mobility group box chromosomal protein 1 antibodies improve survival of rats with sepsis. World J Surg. 2006; 30: 1-8
|
|
|
|
|
|
18) Abraham E, Arcaroli J, Carmody A, et al. HMG-1 as a mediator of acute lung inflammation. J Immunol. 2000; 165: 2950-4
|
|
|
|
|
|
19) Ueno H, Matsuda T, Hashimoto S, et al. Contributions of high mobility group box protein in experimental and clinical acute lung injury. Am J Respir Crit Care Med. 2004; 170: 1310-6
|
|
|
|
|
|
20) Schmidt AM, Yan SD, Yan SF, et al. The multiligand receptor RAGE as a progression factor amplifying immune and inflammatory responses. J Clin Invest. 2001; 108: 949-55
|
|
|
|
|
|
21) Ramasamy R, Yan SF, Schmidt AM. RAGE: therapeutic target and biomarker of the inflammatory response─the evidence mounts. J Leukoc Biol. 2009; 86: 505-12
|
|
|
|
|
|
22) Uchida T, Shirasawa M, Ware LB, et al. Receptor for advanced glycation end-products is a marker of type I cell injury in acute lung injury. Am J Respir Crit Care Med. 2006; 173: 1008-15
|
|
|
|
|
|
23) Zhang H, Tasaka S, Shiraishi Y, et al. Role of soluble receptor for advanced glycation end-products on endotoxin-induced lung injury. Am J Respir Crit Care Med. 2008; 178: 356-62
|
|
|
|
|
|
24) Briot R, Frank JA, Uchida T, et al. Elevated levels of the receptor for advanced glycation end products, a marker of alveolar epithelial type I cell injury, predict impaired alveolar fluid clearance in isolated perfused human lungs. Chest. 2009; 135: 269-75
|
|
|
|
|
|
25) Liliensiek B, Weigand MA, Bierhaus A, et al. Receptor for advanced glycation end products (RAGE) regulates sepsis but not the adaptive immune response. J Clin Invest. 2004; 113: 1641-50
|
|
|
|
|
|
26) Yonekura H, Yamamoto Y, Sakurai S, et al. Novel splice variants of the receptor for advanced glycation end-products expressed in human vascular endothelial cells and pericytes and their putative roles in diabetes-induced vascular injury. Biochem J. 2003; 370: 1097-109
|
|
|
|
|
|
27) Ogawa EN, Ishizaka A, Tasaka S, et al. Contribution of high-mobility group box-1 to the development of ventilator-induced lung injury. Am J Respir Crit Care Med. 2006; 174: 400-7
|
|
|
|
|
|
28) Reynolds PR, Schmitt RE, Kasteler SD, et al. Receptors for advanced glycation end-products (RAGE) targeting protect against hyperoxia-induced lung injury in mice. Am J Respir Cell Mol Biol (in press)
|
|
|
|
|
|
29) Takamiya R, Hung CC, Hall SR, et al. High-mobility group box 1 contributes to lethality of endotoxemia in heme oxygenase-1-deficient mice. Am J Respir Cell Mol Biol. 2009; 41: 129-35
|
|
|
|
|
|
30) Bianchi ME. DAMPs, PAMPs and alarmins: all we need to know about danger. J Leukoc Biol. 2007; 81: 1-5
|
|
|
|
|